Source | Evidence on protein | Close homologs |
---|---|---|
Cuervo et al. | no | yes: 0 |
Hassani et al. | no | yes: 0 |
Forrest at al. (metacyclic) | no | yes: 0 |
Forrest at al. (procyclic) | no | yes: 0 |
Silverman et al. | no | yes: 0 |
Pissara et al. | no | yes: 15 |
Source | Evidence on protein | Close homologs |
---|---|---|
Pires et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Silverman et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Jamdhade et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
DeepLoc | ||
SignalP6 | no | yes: 0, no: 22 |
NetGPI | no | yes: 0, no: 22 |
Term | Name | Level | Count |
---|---|---|---|
GO:0005737 | cytoplasm | 2 | 2 |
GO:0005777 | peroxisome | 6 | 1 |
GO:0020015 | glycosome | 7 | 1 |
GO:0042579 | microbody | 5 | 1 |
GO:0043226 | organelle | 2 | 1 |
GO:0043227 | membrane-bounded organelle | 3 | 1 |
GO:0043229 | intracellular organelle | 3 | 1 |
GO:0043231 | intracellular membrane-bounded organelle | 4 | 1 |
GO:0110165 | cellular anatomical entity | 1 | 2 |
Related structures:
AlphaFold database: A4HKE1
Term | Name | Level | Count |
---|---|---|---|
GO:0000290 | deadenylation-dependent decapping of nuclear-transcribed mRNA | 8 | 2 |
GO:0000956 | nuclear-transcribed mRNA catabolic process | 7 | 2 |
GO:0006139 | nucleobase-containing compound metabolic process | 3 | 2 |
GO:0006401 | RNA catabolic process | 5 | 2 |
GO:0006402 | mRNA catabolic process | 6 | 2 |
GO:0006725 | cellular aromatic compound metabolic process | 3 | 2 |
GO:0006807 | nitrogen compound metabolic process | 2 | 2 |
GO:0008152 | metabolic process | 1 | 2 |
GO:0009056 | catabolic process | 2 | 2 |
GO:0009057 | macromolecule catabolic process | 4 | 2 |
GO:0009892 | negative regulation of metabolic process | 4 | 2 |
GO:0009987 | cellular process | 1 | 2 |
GO:0010468 | regulation of gene expression | 5 | 2 |
GO:0010605 | negative regulation of macromolecule metabolic process | 5 | 2 |
GO:0010629 | negative regulation of gene expression | 6 | 2 |
GO:0016070 | RNA metabolic process | 5 | 2 |
GO:0016071 | mRNA metabolic process | 6 | 2 |
GO:0019222 | regulation of metabolic process | 3 | 2 |
GO:0019439 | aromatic compound catabolic process | 4 | 2 |
GO:0034641 | cellular nitrogen compound metabolic process | 3 | 2 |
GO:0034655 | nucleobase-containing compound catabolic process | 4 | 2 |
GO:0043170 | macromolecule metabolic process | 3 | 2 |
GO:0044237 | cellular metabolic process | 2 | 2 |
GO:0044238 | primary metabolic process | 2 | 2 |
GO:0044248 | cellular catabolic process | 3 | 2 |
GO:0044260 | obsolete cellular macromolecule metabolic process | 3 | 2 |
GO:0044265 | obsolete cellular macromolecule catabolic process | 4 | 2 |
GO:0044270 | cellular nitrogen compound catabolic process | 4 | 2 |
GO:0046483 | heterocycle metabolic process | 3 | 2 |
GO:0046700 | heterocycle catabolic process | 4 | 2 |
GO:0048519 | negative regulation of biological process | 3 | 2 |
GO:0050789 | regulation of biological process | 2 | 2 |
GO:0060255 | regulation of macromolecule metabolic process | 4 | 2 |
GO:0065007 | biological regulation | 1 | 2 |
GO:0071704 | organic substance metabolic process | 2 | 2 |
GO:0090304 | nucleic acid metabolic process | 4 | 2 |
GO:0110154 | RNA decapping | 6 | 2 |
GO:0110156 | methylguanosine-cap decapping | 7 | 2 |
GO:1901360 | organic cyclic compound metabolic process | 3 | 2 |
GO:1901361 | organic cyclic compound catabolic process | 4 | 2 |
GO:1901575 | organic substance catabolic process | 3 | 2 |
Term | Name | Level | Count |
---|---|---|---|
GO:0003824 | catalytic activity | 1 | 23 |
GO:0016787 | hydrolase activity | 2 | 23 |
GO:0016462 | pyrophosphatase activity | 5 | 17 |
GO:0016817 | hydrolase activity, acting on acid anhydrides | 3 | 17 |
GO:0016818 | hydrolase activity, acting on acid anhydrides, in phosphorus-containing anhydrides | 4 | 17 |
GO:0050072 | obsolete m7G(5')pppN diphosphatase activity | 6 | 2 |
Leishmania | From | To | Domain/Motif | Score |
---|---|---|---|---|
CLV_NRD_NRD_1 | 1 | 3 | PF00675 | 0.669 |
CLV_NRD_NRD_1 | 30 | 32 | PF00675 | 0.268 |
CLV_NRD_NRD_1 | 76 | 78 | PF00675 | 0.396 |
CLV_PCSK_KEX2_1 | 30 | 32 | PF00082 | 0.315 |
CLV_PCSK_KEX2_1 | 76 | 78 | PF00082 | 0.339 |
CLV_PCSK_SKI1_1 | 125 | 129 | PF00082 | 0.190 |
CLV_PCSK_SKI1_1 | 174 | 178 | PF00082 | 0.289 |
CLV_PCSK_SKI1_1 | 89 | 93 | PF00082 | 0.443 |
DEG_Nend_UBRbox_1 | 1 | 4 | PF02207 | 0.457 |
DOC_MAPK_gen_1 | 13 | 21 | PF00069 | 0.566 |
DOC_MAPK_gen_1 | 30 | 37 | PF00069 | 0.265 |
DOC_MAPK_MEF2A_6 | 30 | 37 | PF00069 | 0.341 |
DOC_PP1_RVXF_1 | 172 | 179 | PF00149 | 0.425 |
DOC_USP7_MATH_1 | 206 | 210 | PF00917 | 0.568 |
DOC_USP7_UBL2_3 | 13 | 17 | PF12436 | 0.446 |
DOC_USP7_UBL2_3 | 133 | 137 | PF12436 | 0.272 |
DOC_USP7_UBL2_3 | 193 | 197 | PF12436 | 0.652 |
DOC_WW_Pin1_4 | 67 | 72 | PF00397 | 0.366 |
LIG_BRCT_BRCA1_1 | 40 | 44 | PF00533 | 0.194 |
LIG_FHA_1 | 216 | 222 | PF00498 | 0.482 |
LIG_FHA_2 | 111 | 117 | PF00498 | 0.473 |
LIG_FHA_2 | 223 | 229 | PF00498 | 0.457 |
LIG_FHA_2 | 77 | 83 | PF00498 | 0.417 |
LIG_LIR_Gen_1 | 78 | 87 | PF02991 | 0.316 |
LIG_LIR_Nem_3 | 144 | 149 | PF02991 | 0.326 |
LIG_LIR_Nem_3 | 172 | 176 | PF02991 | 0.325 |
LIG_LIR_Nem_3 | 78 | 83 | PF02991 | 0.321 |
LIG_LYPXL_S_1 | 145 | 149 | PF13949 | 0.300 |
LIG_LYPXL_yS_3 | 146 | 149 | PF13949 | 0.300 |
LIG_PDZ_Class_2 | 227 | 232 | PF00595 | 0.467 |
LIG_SH2_STAT5 | 150 | 153 | PF00017 | 0.301 |
LIG_SH3_3 | 94 | 100 | PF00018 | 0.449 |
LIG_TRAF2_1 | 225 | 228 | PF00917 | 0.457 |
LIG_TRAF2_1 | 70 | 73 | PF00917 | 0.447 |
LIG_TRAF2_1 | 79 | 82 | PF00917 | 0.432 |
LIG_UBA3_1 | 148 | 156 | PF00899 | 0.216 |
LIG_UBA3_1 | 180 | 187 | PF00899 | 0.181 |
MOD_CK1_1 | 198 | 204 | PF00069 | 0.407 |
MOD_CK1_1 | 213 | 219 | PF00069 | 0.426 |
MOD_CK2_1 | 110 | 116 | PF00069 | 0.471 |
MOD_CK2_1 | 206 | 212 | PF00069 | 0.635 |
MOD_CK2_1 | 222 | 228 | PF00069 | 0.719 |
MOD_CK2_1 | 62 | 68 | PF00069 | 0.287 |
MOD_CK2_1 | 76 | 82 | PF00069 | 0.375 |
MOD_GlcNHglycan | 125 | 128 | PF01048 | 0.397 |
MOD_GlcNHglycan | 200 | 203 | PF01048 | 0.498 |
MOD_GlcNHglycan | 40 | 43 | PF01048 | 0.181 |
MOD_GSK3_1 | 119 | 126 | PF00069 | 0.211 |
MOD_GSK3_1 | 206 | 213 | PF00069 | 0.671 |
MOD_GSK3_1 | 67 | 74 | PF00069 | 0.322 |
MOD_N-GLC_1 | 222 | 227 | PF02516 | 0.454 |
MOD_N-GLC_1 | 38 | 43 | PF02516 | 0.194 |
MOD_NEK2_1 | 210 | 215 | PF00069 | 0.470 |
MOD_NEK2_1 | 57 | 62 | PF00069 | 0.386 |
MOD_PKA_1 | 76 | 82 | PF00069 | 0.181 |
MOD_PKA_2 | 29 | 35 | PF00069 | 0.296 |
MOD_PKA_2 | 76 | 82 | PF00069 | 0.349 |
MOD_Plk_1 | 6 | 12 | PF00069 | 0.441 |
MOD_Plk_1 | 89 | 95 | PF00069 | 0.469 |
MOD_Plk_4 | 206 | 212 | PF00069 | 0.481 |
MOD_Plk_4 | 89 | 95 | PF00069 | 0.428 |
MOD_ProDKin_1 | 67 | 73 | PF00069 | 0.366 |
MOD_SUMO_rev_2 | 183 | 189 | PF00179 | 0.317 |
TRG_DiLeu_BaEn_2 | 39 | 45 | PF01217 | 0.350 |
TRG_DiLeu_LyEn_5 | 144 | 149 | PF01217 | 0.233 |
TRG_ENDOCYTIC_2 | 146 | 149 | PF00928 | 0.316 |
TRG_ER_diArg_1 | 29 | 31 | PF00400 | 0.315 |
TRG_Pf-PMV_PEXEL_1 | 2 | 7 | PF00026 | 0.451 |
Protein | Taxonomy | Sequence identity | Coverage |
---|---|---|---|
A0A0N0P5P0 | Leptomonas seymouri | 28% | 100% |
A0A0N0P9K0 | Leptomonas seymouri | 50% | 99% |
A0A1X0P292 | Trypanosomatidae | 41% | 76% |
A0A1X0P2U2 | Trypanosomatidae | 28% | 100% |
A0A3Q8IFW7 | Leishmania donovani | 48% | 95% |
A0A3Q8IL17 | Leishmania donovani | 63% | 89% |
A0A3S5H5F7 | Leishmania donovani | 30% | 100% |
A0A422NYC4 | Trypanosoma rangeli | 26% | 100% |
A0A422P4Y4 | Trypanosoma rangeli | 36% | 97% |
A4H455 | Leishmania braziliensis | 31% | 100% |
A4HSD8 | Leishmania infantum | 30% | 100% |
A4I7W9 | Leishmania infantum | 48% | 95% |
C9ZPX0 | Trypanosoma brucei gambiense (strain MHOM/CI/86/DAL972) | 29% | 100% |
C9ZQT5 | Trypanosoma brucei gambiense (strain MHOM/CI/86/DAL972) | 39% | 77% |
E9AKB3 | Leishmania mexicana (strain MHOM/GT/2001/U1103) | 31% | 100% |
E9B2T0 | Leishmania mexicana (strain MHOM/GT/2001/U1103) | 48% | 95% |
Q4Q5C7 | Leishmania major | 47% | 100% |
Q4Q5C8 | Leishmania major | 70% | 100% |
Q4QJJ4 | Leishmania major | 32% | 100% |
V5BU70 | Trypanosoma cruzi | 42% | 90% |
V5DQQ5 | Trypanosoma cruzi | 41% | 90% |